HHS Gives Liability Shield For ZMapp Ebola Treatment Clinical Studies

HHS recently offered liability immunity for the experimental Ebola treatment ZMapp, which has been developed under a contract between the department and California-based Mapp Biopharmaceutical Inc. The two-year liability immunity is retroactive to Feb. 27, when a clinical trial of ZMapp began in Liberia and the United States by the National Institute of Allergy and Infectious Diseases (NIAID). The liability immunity shields the manufacturer, distributors, program planners and licensed health professionals or other individuals who prescribe, administer or dispense ZMapp...